FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer

被引：0
|
作者：
F Bertolini
N Malavasi
L Scarabelli
F Fiocchi
B Bagni
C Del Giovane
G Colucci
G E Gerunda
R Depenni
S Zironi
A Fontana
E Pettorelli
G Luppi
P F Conte
机构：
[1] Oncology,Haematology and Respiratory Diseases Department
[2] University Hospital of Modena,Nuclear Medicine Division
[3] Radiology Institute,Multiorgan Transplantation Division
[4] University Hospital of Modena,undefined
[5] University Hospital of Modena,undefined
[6] General Surgery,undefined
[7] Vignola Hospital,undefined
[8] Azienda USL Modena,undefined
[9] University Hospital of Modena,undefined
来源：
British Journal of Cancer | 2011年 / 104卷
关键词：
bevacizumab; liver metastases; colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1079 / 1084
页数：5
相关论文
共 50 条
  • [1] FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
    Bertolini, F.
    Malavasi, N.
    Scarabelli, L.
    Fiocchi, F.
    Bagni, B.
    Del Giovane, C.
    Colucci, G.
    Gerunda, G. E.
    Depenni, R.
    Zironi, S.
    Fontana, A.
    Pettorelli, E.
    Luppi, G.
    Conte, P. F.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1079 - 1084
  • [2] FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer: Results of a phase II trial and role of PET-CT as early predictor of reponse.
    Bertolini, F.
    Malavasi, N.
    Scarabelli, L.
    Gerunda, G. E.
    Colucci, G.
    Fontana, A.
    Depenni, R.
    Zironi, S.
    Luppi, G.
    Conte, P. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Modified FOLFOX6 and Bevacizumab As Neoadjuvant Chemotherapy for Patients With Potentially Curable Bilobar Liver Metastases From Colorectal Cancer
    Maeda, Atsuyuki
    Isogai, Masatoshi
    Kaneoka, Yuji
    GASTROENTEROLOGY, 2013, 144 (05) : S1079 - S1079
  • [4] The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases.
    Emi, Yasunori
    Muro, Kei
    Yamanaka, Takeharu
    Katayose, Yu
    Uetake, Hiroyuki
    Sugihara, Kenichi
    Kakeji, Yoshihiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] Phase II trial of FOLFOX6, bevacizumab and cetuximab in patients with Colorectal Cancer
    Ocean, A. J.
    O'Brien, K.
    Lee, J.
    Matthews, N.
    Holloway, S.
    Christos, P.
    Kung, T. S.
    Kaubisch, A.
    Chen, H.
    Wadler, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Liver Transplantation for Non-Resectable Liver Metastases from Colorectal Cancer
    Hagness, M.
    Foss, A.
    Line, P. -D.
    Scholz, T.
    Jorgensen, P. F.
    Fosby, B.
    Boberg, K. M.
    Mathisen, O.
    Gladhaug, I. P.
    Hausken, J.
    Dueland, S.
    TRANSPLANTATION, 2012, 94 (10) : 50 - 50
  • [7] Liver Transplantation for Non-Resectable Liver Metastases from Colorectal Cancer
    Hagness, Morten
    Foss, Aksel
    Line, Pal-Dag
    Scholz, Tim
    Jorgensen, Pal F.
    Fosby, Bjarte
    Boberg, Kirsten M.
    Mathisen, Oystein
    Gladhaug, Ivar P.
    Egge, Tor S.
    Solberg, Steinar
    Hausken, John
    Dueland, Svein
    LIVER TRANSPLANTATION, 2012, 18 : S140 - S140
  • [8] Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4
    Dzunic, Miljana
    Andjelkovic-Apostolovic, Marija
    Vrbic, Svetislav
    Pejcic, Ivica
    Petkovic, Ivan
    Cvetanovic, Ana
    Dinic, Sasa
    JOURNAL OF BUON, 2020, 25 (01): : 212 - 219
  • [9] Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
    Otsu, Satoshi
    Hirashima, Yoshinori
    Nishikawa, Kazuo
    Sakashita, Hiroyuki
    Morinaga, Ryotaro
    Watanabe, Koichiro
    Shirao, Kuniaki
    JAPANESE CLINICAL MEDICINE, 2014, 5 : 19 - 23
  • [10] A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
    Matsumura, Masaru
    Hasegawa, Kiyoshi
    Oba, Masaru
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Morita, Satoshi
    Takahashi, Keiichi
    Unno, Michiaki
    Shimada, Yasuhiro
    Muro, Kei
    Matsuhashi, Nobuhisa
    Mori, Masaki
    Baba, Hideo
    Shimada, Mitsuo
    Mise, Yoshihiro
    Kawaguchi, Yoshikuni
    Kagimura, Tatsuo
    Ishigure, Kiyoshi
    Saiura, Akio
    Sugihara, Kenichi
    Kokudo, Norihiro
    LANGENBECKS ARCHIVES OF SURGERY, 2022, 407 (04) : 1345 - 1356
12345